buccal semaglutide reviews FDA Approves Oral Semaglutide: First GLP-1 Pill for Weight Loss Oral Semaglutide In Colleyville, TX

Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members

In the United States, by contrast, the Dietary Supplement Health and Education Act of 1994 classifies herbal products as dietary supplements, a product category that does not require pre-approval

Those with a BMI of 27 or higher and weight-related conditions like high blood pressure or high cholesterol

A drug placed on a preferred tier carried a lower patient copay

2001;163(3 Pt 1):62432